An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup

• Príomhchruthaitheoirí: Léonore Diezi (Údar), Kim Dao (Údar), Vincent Jullien (Údar), Caroline Roussel‐Maupetit (Údar), Ingrid Burton (Údar), Pascal André (Údar), Carine Bardinet (Údar), Laura E. Rothuizen (Údar), Haithem Chtioui (Údar), Maria A. Manso‐Silvan (Údar), Catherine Guittet (Údar), Françoise Brunner‐Ferber (Údar), Francois Vandenhende (Údar), Catherine Chiron (Údar), Luc‐André Granier (Údar), Thierry Buclin (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Wiley, 2023-02-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Abstract Ethosuximide, the first‐line therapy for childhood absence epilepsy, is currently formulated as a syrup (Zarontin®, Pfizer) with a bitter taste and high sugar content, poorly adapted to children, and a ketogenic diet. The collaborative European FP7 project KIEKIDS aimed at developing an inn...